Cargando…

A Signature Based on Costimulatory Molecules for the Assessment of Prognosis and Immune Characteristics in Patients With Stomach Adenocarcinoma

Although costimulatory molecules have been shown to boost antitumor immune responses, their significance in stomach adenocarcinoma (STAD) remains unknown. The purpose of this study was to examine the gene expression patterns of costimulatory molecule genes in patients with STAD and develop a predict...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Bangjie, Yao, Yong, Mao, Deshen, Li, Conghan, Wang, Xingyu, Sheng, Shuyan, Zhang, Lizhi, Wang, Xinyi, Chen, Sanwei, Xu, Wentao, Deng, Jianyi, Sun, Chenyu, Zhou, Qin, Lowe, Scott, Bentley, Rachel, Shao, Wei, Li, Haiwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353527/
https://www.ncbi.nlm.nih.gov/pubmed/35935979
http://dx.doi.org/10.3389/fimmu.2022.928742
_version_ 1784762883858497536
author Chen, Bangjie
Yao, Yong
Mao, Deshen
Li, Conghan
Wang, Xingyu
Sheng, Shuyan
Zhang, Lizhi
Wang, Xinyi
Chen, Sanwei
Xu, Wentao
Deng, Jianyi
Sun, Chenyu
Zhou, Qin
Lowe, Scott
Bentley, Rachel
Shao, Wei
Li, Haiwen
author_facet Chen, Bangjie
Yao, Yong
Mao, Deshen
Li, Conghan
Wang, Xingyu
Sheng, Shuyan
Zhang, Lizhi
Wang, Xinyi
Chen, Sanwei
Xu, Wentao
Deng, Jianyi
Sun, Chenyu
Zhou, Qin
Lowe, Scott
Bentley, Rachel
Shao, Wei
Li, Haiwen
author_sort Chen, Bangjie
collection PubMed
description Although costimulatory molecules have been shown to boost antitumor immune responses, their significance in stomach adenocarcinoma (STAD) remains unknown. The purpose of this study was to examine the gene expression patterns of costimulatory molecule genes in patients with STAD and develop a predictive signature to aid in therapy selection and outcome prediction. We used 60 costimulatory family genes from prior research to conduct the first complete costimulatory molecular analysis in patients with STAD. In the two study groups, consensus clustering analysis based on these 60 genes indicated unique distribution patterns and prognostic differences. Using the least absolute shrinkage and selection operator and Cox regression analysis, we identified nine costimulatory molecular gene pairs (CMGPs) with prognostic value. With these nine CMGPs, we were able to develop a costimulatory molecule-related prognostic signature that performed well in an external dataset. For the patients with STAD, the signature was proven to be a risk factor independent of the clinical characteristics, indicating that this signature may be employed in conjunction with clinical considerations. A further connection between the signature and immunotherapy response was discovered. The patients with high mutation rates, an abundance of infiltrating immune cells, and an immunosuppressive milieu were classified as high-risk patients. It is possible that these high-risk patients have a better prognosis for immunotherapy since they have higher cytolytic activity scores and immunophenoscores of CTLA4 and PD-L1/PD-L2 blockers. Therefore, our signature may help clinicians in assessing patient prognosis and developing treatment plans.
format Online
Article
Text
id pubmed-9353527
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93535272022-08-06 A Signature Based on Costimulatory Molecules for the Assessment of Prognosis and Immune Characteristics in Patients With Stomach Adenocarcinoma Chen, Bangjie Yao, Yong Mao, Deshen Li, Conghan Wang, Xingyu Sheng, Shuyan Zhang, Lizhi Wang, Xinyi Chen, Sanwei Xu, Wentao Deng, Jianyi Sun, Chenyu Zhou, Qin Lowe, Scott Bentley, Rachel Shao, Wei Li, Haiwen Front Immunol Immunology Although costimulatory molecules have been shown to boost antitumor immune responses, their significance in stomach adenocarcinoma (STAD) remains unknown. The purpose of this study was to examine the gene expression patterns of costimulatory molecule genes in patients with STAD and develop a predictive signature to aid in therapy selection and outcome prediction. We used 60 costimulatory family genes from prior research to conduct the first complete costimulatory molecular analysis in patients with STAD. In the two study groups, consensus clustering analysis based on these 60 genes indicated unique distribution patterns and prognostic differences. Using the least absolute shrinkage and selection operator and Cox regression analysis, we identified nine costimulatory molecular gene pairs (CMGPs) with prognostic value. With these nine CMGPs, we were able to develop a costimulatory molecule-related prognostic signature that performed well in an external dataset. For the patients with STAD, the signature was proven to be a risk factor independent of the clinical characteristics, indicating that this signature may be employed in conjunction with clinical considerations. A further connection between the signature and immunotherapy response was discovered. The patients with high mutation rates, an abundance of infiltrating immune cells, and an immunosuppressive milieu were classified as high-risk patients. It is possible that these high-risk patients have a better prognosis for immunotherapy since they have higher cytolytic activity scores and immunophenoscores of CTLA4 and PD-L1/PD-L2 blockers. Therefore, our signature may help clinicians in assessing patient prognosis and developing treatment plans. Frontiers Media S.A. 2022-07-22 /pmc/articles/PMC9353527/ /pubmed/35935979 http://dx.doi.org/10.3389/fimmu.2022.928742 Text en Copyright © 2022 Chen, Yao, Mao, Li, Wang, Sheng, Zhang, Wang, Chen, Xu, Deng, Sun, Zhou, Lowe, Bentley, Shao and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Chen, Bangjie
Yao, Yong
Mao, Deshen
Li, Conghan
Wang, Xingyu
Sheng, Shuyan
Zhang, Lizhi
Wang, Xinyi
Chen, Sanwei
Xu, Wentao
Deng, Jianyi
Sun, Chenyu
Zhou, Qin
Lowe, Scott
Bentley, Rachel
Shao, Wei
Li, Haiwen
A Signature Based on Costimulatory Molecules for the Assessment of Prognosis and Immune Characteristics in Patients With Stomach Adenocarcinoma
title A Signature Based on Costimulatory Molecules for the Assessment of Prognosis and Immune Characteristics in Patients With Stomach Adenocarcinoma
title_full A Signature Based on Costimulatory Molecules for the Assessment of Prognosis and Immune Characteristics in Patients With Stomach Adenocarcinoma
title_fullStr A Signature Based on Costimulatory Molecules for the Assessment of Prognosis and Immune Characteristics in Patients With Stomach Adenocarcinoma
title_full_unstemmed A Signature Based on Costimulatory Molecules for the Assessment of Prognosis and Immune Characteristics in Patients With Stomach Adenocarcinoma
title_short A Signature Based on Costimulatory Molecules for the Assessment of Prognosis and Immune Characteristics in Patients With Stomach Adenocarcinoma
title_sort signature based on costimulatory molecules for the assessment of prognosis and immune characteristics in patients with stomach adenocarcinoma
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353527/
https://www.ncbi.nlm.nih.gov/pubmed/35935979
http://dx.doi.org/10.3389/fimmu.2022.928742
work_keys_str_mv AT chenbangjie asignaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma
AT yaoyong asignaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma
AT maodeshen asignaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma
AT liconghan asignaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma
AT wangxingyu asignaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma
AT shengshuyan asignaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma
AT zhanglizhi asignaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma
AT wangxinyi asignaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma
AT chensanwei asignaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma
AT xuwentao asignaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma
AT dengjianyi asignaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma
AT sunchenyu asignaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma
AT zhouqin asignaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma
AT lowescott asignaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma
AT bentleyrachel asignaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma
AT shaowei asignaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma
AT lihaiwen asignaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma
AT chenbangjie signaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma
AT yaoyong signaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma
AT maodeshen signaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma
AT liconghan signaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma
AT wangxingyu signaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma
AT shengshuyan signaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma
AT zhanglizhi signaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma
AT wangxinyi signaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma
AT chensanwei signaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma
AT xuwentao signaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma
AT dengjianyi signaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma
AT sunchenyu signaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma
AT zhouqin signaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma
AT lowescott signaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma
AT bentleyrachel signaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma
AT shaowei signaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma
AT lihaiwen signaturebasedoncostimulatorymoleculesfortheassessmentofprognosisandimmunecharacteristicsinpatientswithstomachadenocarcinoma